WebOur Solution. Cytonics' solution to the OA problem is to deliver high concentrations of Alpha-2-Macroglobulin (A2M), a blood protein that has been shown to protect cartilage, into the joint space to slow and eventually halt the progression of arthritis. A2M functions byinhibiting destructive protease enzymes that chew up cartilage tissue. WebEnter Cytonics, a private research and development company which believes it may have developed a treatment that addresses the root cause of Osteoarthritis. Their treatment method is to deliver high concentrations of Alpha-2-Macroglobulin (A2M), a blood serum protein that has been shown to protect cartilage, into the joint space to slow and ...
Can Cytonics Pivot Successfully to Covid-19 Therapeutics?
WebApr 5, 2024 · Cytonics, with a valuation cap of $32.4 million, is raising Series C funding on SeedInvest. The company is a leader in regenerative medicine and has developed innovative therapies for musculoskeletal diseases like osteoarthritis. Cytonics has created an Autologous Platelet Integrated Concentration system that concentrates A2M from … WebOct 16, 2024 · Cytonics Stock Is an Investment in a ‘Super’ Protein At the heart of this biotechnology story is alpha-2-macroglobulin (A2M), which is a plasma protein found in the blood and is mainly ... greenville tech manufacturing courses
What
WebCytonics Corporation is the leader in cartilage research and focuses on innovative product developments for Osteoarthritis utilizing Alpha-2-Macroglobulin (A2M) therapies. A2M injection therapy has shown … WebJul 18, 2024 · APIC selectively concentrates a blood protein called “A2M” from a patient’s own blood (hence the term “autologous”), and employs a proprietary filtration system to deliver a pure, A2M ... WebCytonics is developing diagnostics and therapeutic medicine for osteoarthritis. Disrupting a $180b industry by pioneering the future of regenerative medicine. ... CYT-108 is a recombinant variant of the … fnf tutorial online sequencer